Business Context and Reporting Period
This Form 8-K filing by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) covers events occurring on July 24, 2012, with a report date of July 27, 2012. The filing details material definitive agreements regarding executive compensation and changes to the Board of Directors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on contractual obligations and governance changes rather than financial performance metrics.
Material Changes
- CEO Compensation: An Amended and Restated Employment Agreement was executed with CEO Mark L. Baum. He becomes eligible for severance equal to one year of base salary plus annual bonus if the company completes a financing raising at least $5,000,000. This eligibility applies to terminations without cause, death, or disability.
- Consultant Restrictions: An amendment to Dr. Kammer's advisory agreement restricts him from selling more than 5% of his acquired shares in any monthly period without Board approval.
- Board Resignation: Dr. Balbir Brar resigned as a director effective July 25, 2012, but remains as President of the company.
- Board Appointment: Steven G. Austin, CPA, was appointed as a new director effective July 26, 2012. He is expected to chair the audit committee.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or general risk factors. However, it highlights a specific contingency: the CEO's severance benefits are contingent upon the company successfully raising $5,000,000 in financing. Additionally, the appointment of a new director with CPA credentials suggests a focus on establishing formal audit committee oversight.
Investor Verification Checklist
- Verify the terms of the $5,000,000 financing contingency required to trigger CEO severance benefits.
- Confirm the vesting schedule and exercise price ($0.90) of the 85,616 stock options granted to new director Steven G. Austin.
- Review the total quarterly cash compensation ($6,250) approved for the new director.
- Check for any subsequent filings regarding the status of the $5,000,000 financing mentioned in the CEO agreement.